<DOC>
	<DOCNO>NCT01958918</DOCNO>
	<brief_summary>This 12-month , phase IV , randomize , open label , multicenter study compare efficacy 0.5 mg ranibizumab pro nata treatment versus 2 mg aflibercept bimonthly intravitreal injection central retinal thickness ( CRT ) stability measure mean CRT fluctuation month 3 month 6 treatment spectral domain optical coherence tomography ( SD-OCT ) explore functional outcome month 12 patient neovascular ( wet ) age-related macular degeneration ( AMD ) . Approximately 500 patient randomize Europe .</brief_summary>
	<brief_title>Efficacy Ranibizumab Prn Treatment Compared Aflibercept Bimonthly Intravitreal Injections Retinal Thickness Stability Patients With Wet AMD</brief_title>
	<detailed_description />
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual impairment predominantly due neovascular AMD Active newly diagnose , untreated , angiographically document , CNV lesion secondary neovascular AMD line Summary product characteristic ranibizumab aflibercept Stroke myocardial infarction le 3 Months prior study entry Active injection inflammation either eye time study entry Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>neovascular AMD</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>aflibercept</keyword>
	<keyword>BCVA</keyword>
	<keyword>SD OCT</keyword>
</DOC>